[Active immune-prophylaxis after allogeneic hematopoietic progenitor cell transplantation in pediatric patients].
There is considerable evidence supporting the disappearance of immunity against diseases for which there is active immune-prophylaxis available after allogeneic hematopoietic progenitor cell transplantation. These findings do not constitute merely an epidemiologic problem. From a strictly clinical point of view, these patients might benefit from the administration of different forms of vaccines against diseases to which they are particularly susceptible. There are, however, no unified criteria for the revaccination of these patients. Moreover, several surveys suggest that active immune-prophylaxis is frequently undervalued in these patients. In the present review, we provide up-to-date information on current trends as well as practical guidelines for the re-immunization of these patients in our environment.
Ortín De Miguel
M
M
Bone Marrow Transplant Unit, Department of Haematology and Oncology, The Birmingham Children's Hospital, Reino Unido. miguel.ortin@talk21.com
Bureo Dacal
E
E
Bonilla Miera
C
C
Lozano De La Torre
M J
MJ
Zubizarreta Ypiña
A
A
D002648:Child; D018380:Hematopoietic Stem Cell Transplantation / Q000592:standards; D006801:Humans; D007115:Immunization Schedule; D014184:Transplantation, Homologous; D014611:Vaccination / Q000592:standards